Kuwano A, Yada M, Tanaka K, Hamamoto T, et al. Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. Anticancer Res 2026;46:5217-5227.
PMID: 42674706